3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
60
Leukemia
32
Gastrointestinal Stromal Tumors
27
Precursor Cell Lymphoblastic Leukemia-Lymphoma
21
Leukemia, Myeloid, Chronic-Phase
21
Blast Crisis
9
Philadelphia Chromosome
8
Neoplasm Metastasis
8
Melanoma
8
Lung Neoplasms
8
Brain Neoplasms
7
Sarcoma
6
Prostatic Neoplasms
6
Neoplasms
6
Recurrence
5
Ovarian Neoplasms
5
Glioblastoma
5
Carcinoma, Non-Small-Cell Lung
5
Small Cell Lung Carcinoma
4
Primary Myelofibrosis
4
Polycythemia Vera
4
Leukemia, Myelomonocytic, Chronic
4
Leukemia, Myeloid, Acute
4
Leukemia, Myeloid, Accelerated Phase
4
Leukemia, Myeloid
4
Dermatofibrosarcoma
4
Carcinoma, Ovarian Epithelial
4
Breast Neoplasms
4
Osteosarcoma
3
Neuroectodermal Tumors, Primitive, Peripheral
3
Interventions
vactosertib
1
Imatinib Mesylate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Dermoid Cyst
×
Imatinib Mesylate
×
Clear all
NCT06219733
2024-12-09
MP-VAC-206
MedPacto, Inc.
Phase 2
Withdrawn